Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

15.990
-0.510-3.09%
Volume:5.74M
Turnover:91.72M
Market Cap:42.52B
PE:10.79
High:16.480
Open:16.480
Low:15.800
Close:16.500
52wk High:28.232
52wk Low:14.505
Shares:2.66B
HK Float Shares:540.97M
Volume Ratio:0.99
T/O Rate:1.06%
Dividend:0.46
Dividend Rate:2.85%
EPS(LYR):1.482
ROE:6.95%
ROA:1.40%
PB:0.75
PE(LYR):10.79
PS:0.86

Loading ...

FOSUN PHARMA's Biosimilar HLX05-N Receives FDA Clearance for US Clinical Trial

Stock News
·
May 10

Fosun Pharma Subsidiary Obtains NMPA Green Light for Venlafaxine Sustained-Release Tablets

Bulletin Express
·
May 08

FOSUN PHARMA's Venlafaxine Hydrochloride Extended-Release Tablets Receive Market Approval

Stock News
·
May 08

Shanghai Fosun Pharma - Drug Registration Application for Venlafaxine Hydrochloride Sustained-Release Tablets Approved by China's Nmpa

THOMSON REUTERS
·
May 08

Sinopharm Group Stock Sheds 1.6% in Hong Kong

Dow Jones
·
May 08

Leadership Reshuffle Sweeps Pharmaceutical Sector: Hengrui, Fosun, AstraZeneca, Pfizer Among Key Players

Deep News
·
May 07

Shanghai Fosun Pharma - Drug Registration Application for Sodium Nitroprusside Injection Approved by Nmpa

THOMSON REUTERS
·
Apr 30

Fosun Pharma Maintains Stable Share Base in April; 0% New Issuance, Public Float Compliant

Bulletin Express
·
Apr 30

FOSUN PHARMA Subsidiary Receives Regulatory Approval for Sodium Nitroprusside Injection

Stock News
·
Apr 30

Fosun Pharmaceutical Reports 14% Higher Profit in Q1

MT Newswires Live
·
Apr 29

Press Release: Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution

Dow Jones
·
Apr 28

Morgan Stanley Raises Fosun Pharma's Revenue Forecast, Sets HK$32 Target with "Overweight" Rating

Stock News
·
Apr 22

FOSUN PHARMA’s 2025 ESG Report Highlights: AA MSCI Rating, RMB 5.91 Billion R&D Spend, and Strong Green, Social Commitments

Bulletin Express
·
Apr 21

Fosun Pharma Releases 2025 ESG and Sustainability Report

Bulletin Express
·
Apr 21

复星医药2025年报:净利润同比增至33.71亿元,业务与治理结构持续优化

Bulletin Express
·
Apr 21

FOSUN PHARMA Announces Release of 2025 Annual Report and Updates Shareholder Communication Arrangements

Bulletin Express
·
Apr 21

BRIEF-Shanghai Fosun Pharma Unit Received Approval From NMPA

Reuters
·
Apr 14

Fosun Pharma Unit Gets China Nod for Amyloidosis Drug Trial

MT Newswires Live
·
Apr 14

Fosun Pharma receives NMPA green light for Phase I/II trials of dual-target CAR-T therapy FKC289

Bulletin Express
·
Apr 14

Shanghai Fosun Pharma - Unit Received Approval From Nmpa for Phase I/Ii Clinical Trial of Fkc289 Injection

THOMSON REUTERS
·
Apr 14